Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2

Download

Analysis of endocrine-resistant LY2 breast cancer cells depleted of p160 steroid coactivator protein SRC-1 and treated with tamoxifen. SRC-1 is central to the development of the endocrine resistant phenotype. Results provide insight into the molecular basis of endocrine resistant breast cancer.

Cancer Type: Breast Cancer

GPL: 570

Number of Genes with Data: 940

Number Observations: 14

Number Outputs: 1

Imbalanced Ratio: 0.75

Default Task: Classification